Kalvista Pharmaceuticals Limited

Simon Teanby Hodgson

David Michael Evans

Rebecca Louise Davie

Hannah Joy Edwards

Alun John Smith

Michael John Stocks

David Edward Clark

Andrew Richard Novak

Thomas Matthew Baker

David Philip Rooker

Stephen John Pethen

Hanna Joy Edwards

Iain Miller

Alessandro Mazzacani

Matthew Robert Conroy

The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R5, R6, R7, A, B, W, X, Y and Z are as defined herein.

Enzyme inhibitors

N-((het)arylmethyl)-heteroaryl-carboxamides compounds as kallikrein inhibitors

The present invention provides a selection of compounds of formula (I): (I) compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R5, R6, R7, A, B, W, X, Y and Z are as defined herein. 

Pyrazole derivatives as plasma kallikrein inhibitors

N-((HET)arylmethyl)-heteroaryl-carboxamides compounds as kallikrein inhibitors

N-((HET)arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors

The present invention provides compounds of formula (I): (I) compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R5, R6, R7, A, B, U, D, E, W, X, Y and Z are as defined herein. 

N-((het) arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors

The present invention provides compounds of formula (I): (I) compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R5, R6, R7, A, B, W, X, Y and Z are as defined herein. 

The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R5, R6, R7, A, B, W, X, Y and Z are as defined herein. 

Heterocyclic derivates

Growing community of inventors

Bedfordshire, United Kingdom

Simon Teanby Hodgson